Table 2.
Baseline and Longitudinal Characteristics by Bacterial Vaginosis Recurrence Status (n = 121)
| Characteristic | Cure (n = 105) | Recurrence (n = 16) | P Valuea |
|---|---|---|---|
| Study | |||
| StepUp studies | 45 (43) | 4 (25) | .274 |
| SToPBV | 60 (57) | 12 (75) | |
| Past history of BV | |||
| No | 30 (29) | 2 (12) | .232 |
| Yes | 75 (71) | 14 (88) | |
| Antibiotic prescribed | |||
| Oral metronidazole | 92 (88) | 14 (87.5) | 1.000 |
| Intravaginal clindamycin | 12 (11) | 2 (12.5) | |
| Intravaginal metronidazole | 1 (1) | 0 (0) | |
| 100% treatment adherenceb | |||
| No | 10 (10) | 2 (12) | .662 |
| Yes | 94 (90) | 14 (88) | |
| Characteristics between day 0 and study endpoint | |||
| Any hormonal contraceptive usec | |||
| No | 55 (52) | 9 (56) | .796 |
| Yes | 50 (48) | 7 (44) | |
| Any IUD used | |||
| No | 94 (90) | 13 (81) | .396 |
| Yes | 11 (10) | 3 (19) | |
| Any douching | |||
| No | 94 (90) | 15 (94) | 1.000 |
| Yes | 11 (10) | 1 (6) | |
| Any smoking | |||
| No | 68 (65) | 8 (50) | .271 |
| Yes | 36 (35) | 8 (50) | |
| Any penile–vaginal sex | |||
| No | 28 (27) | 1 (6) | .114 |
| Yes | 77 (73) | 15 (94) | |
| Condom use for penile–vaginal sex | |||
| Always/no penile–vaginal sex | 38 (36) | 6 (38) | 1.000 |
| Not always | 67 (64) | 10 (62) | |
| Any receptive oral sex | |||
| No | 42 (40) | 5 (31) | .590 |
| Yes | 63 (60) | 11 (69) | |
| Any anal sex | |||
| No | 93 (89) | 12 (75) | .225 |
| Yes | 12 (11) | 4 (25) | |
| Any sex with an RSP | |||
| No | 44 (42) | 3 (19) | .100 |
| Yes | 61 (58) | 13 (81) | |
| RSP treatment details | |||
| No RSP | 41 (39) | 3 (19) | .007 |
| Treated RSP | 45 (43) | 4 (25) | |
| Untreated RSP | 19 (18) | 9 (56) | |
| Any new sexual partner | |||
| No | 85 (81) | 13 (81) | 1.000 |
| Yes | 20 (19) | 3 (19) | |
Data are presented as No. (%) unless otherwise indicated. P values <.05 are bolded to indicate statistically significant associations.
Abbreviations: BV, bacterial vaginosis; IUD, intrauterine device; RSP, regular sexual partner; SToPBV, Strategies to prevent BV.
The χ2 or Fisher exact test was used for categorical data and Wilcoxon signed-rank test was used for continuous variables.
Antibiotics prescribed included oral metronidazole (n = 106), intravaginal clindamycin (n = 14), and intravaginal metronidazole (n = 1). One woman did not report adherence data.
Between day 0 and month 1, 44 women reported current oral contraceptive use, 6 reported using a levonorgestrel IUD, 6 reported using a contraceptive implant, and 1 reported using a hormonal injection (Depo-Provera).
Between day 0 and month 1, 6 women reported using a levonorgestrel IUD and 8 women reported using a copper IUD. Of the 3 women with an IUD in situ who experienced recurrence, 2 reported using a copper IUD and 1 reported using a levonorgestrel IUD.